XRCC3 T241M Polymorphism and Bladder Cancer Risk: A Meta-analysis

Objectives To evaluate the role of the X-ray repair cross complementing group 3 (XRCC3) T241M polymorphism in bladder cancer susceptibility. Studies of the polymorphism of XRCC3 have shown inconclusive trends in the risk of bladder cancer. Methods We performed a meta-analysis of all available studies, which included 5298 cases and 6614 controls. Results Overall, a significant risk effect of the T241M polymorphism was found under homologous contrast (MM vs TT; P = .02, odds ratio [OR] 1.16, 95% confidence interval [CI] 1.02-1.33). Subtle, but insignificantly increased, risks were observed under recessive model contrast [MM vs (MT+TT); P = .05, OR 1.13, 95% CI 1.00-1.27] in all subjects, with homologous contrast ( P = .05, OR 1.16, 95% CI 1.00-1.34) and recessive model contrast ( P = .06, OR 1.13, 95% CI 0.99-1.29) observed in the European subgroup. Conclusions Taken together, our meta-analysis had suggested an increased risk role of XRCC3 241MM genotype in bladder cancer among all subjects, and the effect of T241M polymorphism on bladder susceptibility should be studied with a larger, stratified population.